dexfenfluramine
Trade name: Redux
Approved
May 1, 1996
Dexfenfluramine, formerly sold under the brand name Redux, is a serotonergic drug that was used as an appetite suppressant to promote weight loss. It is the d-enantiomer of fenfluramine and is structurally similar to amphetamine, but lacks any psychologically stimulating effects. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 1 marketing orgs
Earliest trial started Apr 1, 2006 (NCT01296802)
Timeline
1990s
- May 1, 1996
Earliest FDA Approval
Indications
Approved for
Mechanism of action
- Serotonin (5-HT) receptorAGONIST
Serotonin (5-HT) receptor agonist
It reduces appetite by increasing the amount of extracellular serotonin in the brain. Dexfenfluramine is an anorectic agent that acts by enhancing serotonergic transmission through inhibition of 5-HT reuptake by the parent compound, and through its major circulating des-ethylated metabolite, dexnorfenfluramine, which is a 5-HT reuptake inhibitor, a 5-HT and noradrenaline releasing agent, and a potent agonist at postsynaptic 5-HT2 receptors.
- 5-hydroxytryptamine receptor 1F (HTR1F) ↗
- 5-hydroxytryptamine receptor 2B (HTR2B) ↗
- 5-hydroxytryptamine receptor 4 (HTR4) ↗
- 5-hydroxytryptamine receptor 1B (HTR1B) ↗
- 5-hydroxytryptamine receptor 3A (HTR3A) ↗
- 5-hydroxytryptamine receptor 1A (HTR1A) ↗
- 5-hydroxytryptamine receptor 1D (HTR1D) ↗
- 5-hydroxytryptamine receptor 2A (HTR2A) ↗
- 5-hydroxytryptamine receptor 2C (HTR2C) ↗
- 5-hydroxytryptamine receptor 1E (HTR1E) ↗
- 5-hydroxytryptamine receptor 7 (HTR7) ↗
- 5-hydroxytryptamine receptor 6 (HTR6) ↗
- 5-hydroxytryptamine receptor 5A (HTR5A) ↗
- 5-hydroxytryptamine receptor 3E (HTR3E) ↗
- 5-hydroxytryptamine receptor 3B (HTR3B) ↗
- 5-hydroxytryptamine receptor 3D (HTR3D) ↗
- 5-hydroxytryptamine receptor 3C (HTR3C) ↗
- Serotonin 1a (5-HT1a) receptor
- Serotonin 1d (5-HT1d) receptor
- Serotonin 1b (5-HT1b) receptor
- Serotonin 2a (5-HT2a) receptor
- Serotonin 2c (5-HT2c) receptor
- Serotonin 3a (5-HT3a) receptor
- Serotonin 4 (5-HT4) receptor
- Serotonin 2b (5-HT2b) receptor
- Serotonin 1f (5-HT1f) receptor
- Serotonin 7 (5-HT7) receptor
- Serotonin 1e (5-HT1e) receptor
- Serotonin 5a (5-HT5a) receptor
- Serotonin 6 (5-HT6) receptor
- Serotonin 3 (5-HT3) receptor
- Serotonin 2 (5-HT2) receptor
- Serotonin 1 receptors; 5-HT1B & 5-HT1D
- Serotonin 2 receptors; 5-HT2a & 5-HT2c
- Serotonin receptor (2b and 2c)
- Serotonin 3 (5-HT3) receptor
- Serotonin 1 (5-HT1) receptor
- Serotonin 3b (5-HT3b) receptor
- 5-hydroxytryptamine receptor 3A/3E
- 5-hydroxytryptamine receptor 3A/3C
- 5-HT1A/5-HT1F
- 5-HT1D/5-HT1F
- 5-HT1B/5-HT1F
Approval history
- approvedMay 1, 1996
Chemistry & pharmacology
SMILES
CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1- Mol. weight
- 231.26 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL248702 ↗
- WikipediaDexfenfluramine ↗
- ChEMBLCHEMBL1887891 ↗
Also known as
- adifax
- adifax
- dexfenfluramina
- dexfenfluramina
- dexfenfluramine
- dexfenfluramine
- dexfenfluramine
- dexfenfluramine
- dexfenfluramine
- dexfenfluramine
- dexfenfluramine
- dexfenfluramine
- dexfenfluramine
- dexfenfluramine
- dexfenfluramine
- dexfenfluramine hcl
- dexfenfluramine hcl
- dexfenfluramine hcl
- dexfenfluramine hydrochloride
- dexfenfluramine hydrochloride
- dexfenfluramine hydrochloride
- dexfenfluraminum
- dexfenfluraminum
- dextrofenfluramine
- dextrofenfluramine
- dextrofenfluramine
- d-fenfluramine
- d-n-ethyl-alpha-methyl-m-trifluoromethylphenethylamine
- d-n-ethyl-alpha-methyl-m-trifluoromethylphenethylamine
- (+)-fenfluramine
- (+)-fenfluramine
- (+)-fenfluramine
- redux
- redux
- redux
- s-5614 hcl
- s-5614 hcl
- (s)-fenfluramine
- (s)-fenfluramine
- (s)-fenfluramine
- (s)-n-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine
- (s)-n-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01296802 | N/A | Apr 1, 2006 | University of Zurich |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Zurich | Academic/Hospital | 1 | 1 | 1 | 2006 |
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| American Home Products | For profit | NDA | — |